Keynote: Europe's Biotech Act II: Setting the Manufacturing Foundation
Day 2 Next-Gen Bio Stage
07/10/2026 11:00 - 11:30am
Contributors
Claire Skentelbery : Director General - EuropaBio
With the EU Biotech Act II launching Q4 2026, Europe stands at a critical juncture where policy ambition must translate into manufacturing reality. This keynote establishes the strategic context: how legislative frameworks, infrastructure investment, and ecosystem coordination are converging to position European bio-manufacturing as a competitive advantage in the global biotechnology landscape.
Key Themes:
- Legislative Architecture: How Biotech Act II's regulatory streamlining, harmonised approval pathways, and innovation incentives create the policy foundation for manufacturing scale-up across therapeutics, industrial biotech, and circular bioeconomy applications.
- Infrastructure Readiness: The gap between Europe's scientific excellence and manufacturing execution capability—and what Biotech Act II aims to address through funding mechanisms, facility investment, and workforce development.
- Strategic Positioning: Why manufacturing readiness is becoming Europe's competitive differentiator against US and Asian markets, and how policy frameworks enable faster commercialisation timelines.